PREOPERATIVE PARAMETERS | |
Demographic details | |
Age in years; median (IQR) | 54 (52–57) |
BMI in kg/m2; median (IQR) | 29 (24.7–34.3) |
Comorbidities; n (%) | |
Diabetes mellitus | 2 (25) |
Hypertension | 1 (12.5) |
COPD/Asthma | 0 (0) |
Cerebrovascular disease | 2 (25) |
Prior abdominal surgeries | 0 (0) |
American Society of Anesthesiologists score; median (IQR) | 2 (1–3) |
Tumor characteristics | |
PSA in ng/mL; median (IQR) | 4.4 (3.8–6.1) |
Clinical tumor stage; n (%) | |
cT1 | 5 (62.5) |
cT2a | 3 (37.5) |
Transrectal ultrasound-guided biopsy (12–16 cores) | |
Highest Gleason score; n (%) | 5 (62.5) |
3+3 | 4 (50) |
3+4 | 4 (50) |
Number of positive cores; median (IQR) | 3.5 (2–5) |
Percent core positivity; median (IQR) | 29.2 (16.7–41.7) |
Unilateral disease (core positivity limited to one side); n (%) | 6 (75) |
Preoperative IIEF-5 score; median (IQR) | 24 (23–25) |
Preoperative IPSS score; median (IQR) | 3 (2.5–3.5) |
BMI, body mass index; COPD, chronic obstructive pulmonary disease; IIEF-5, International Index of Erectile Function; IPSS, International Prostate Symptom Score; IQR, IQR range; PSA, prostate specific antigen.